Loading clinical trials...
Loading clinical trials...
Tb-PSMA-I&T Radionuclide Neo-Adjuvant Treatment in Patients With Locally Advanced Prostate Cancer Before Radical Prostatectomy: TbeforePROST Trial.
This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate cancer. Our aim is to evaluate the use of a novel treatment (Tb-PSMA) prior to the surgical removal of the prostate. This treatment has already shown initial promising results in patients with metastatic prostate cancer but has never been tested for locally advanced disease before surgery.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Beilinson Hospital
Petah Tikva, Israel
Start Date
August 12, 2025
Primary Completion Date
August 12, 2028
Completion Date
August 12, 2028
Last Updated
October 6, 2025
20
ESTIMATED participants
Tb-PSMA-I&T (Tb-PSMA)
DRUG
Lead Sponsor
Rabin Medical Center
NCT05406999
NCT07393867
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions